English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Significance Treatment of acute myelogenous leukemia (AML) has witnessed tremendous progress over the past three decades, owing mainly to the introduction of anthracycline/cytarabine-based protocols. However, a sizable proportion of patients with AML experience relapse or are refractory to standard therapy. Our study addressed a unique molecular/cellular mechanism of Homoharringtonine (HHT) among the known anticancer drugs. A different mode of action of HHT compared with the currently used main anti-AML therapeutics is its ability to directly target NKRF protein and the resultant down-regulation of theMYC gene, a driver of leukemogenesis. Our observation suggests that expression ofMYC together withKIT could be a biomarker in patients with AML suitable for HHT treatment.

Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-κB repressing factor